Stroke prevention in atrial fibrillation

Journal of Cardiovascular Medicine

Volumn 13, Issue 2, 2012, Pages 73-85

  Mohammed, Ilyas ^a,b   Mohmand Borkowski, Adam ^a,b   Burke, James F ^a,b   Kowey, Peter R ^a,b  

^a LANKENAU HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

atrial fibrillation; stroke; therapy

Indexed keywords

ACETYLSALICYLIC ACID; AMINOTRANSFERASE; ANTIARRHYTHMIC AGENT; ANTIVITAMIN K; APIXABAN; CD63 ANTIGEN; CLARITHROMYCIN; CLOPIDOGREL; DABIGATRAN; EDOXABAN; ERYTHROMYCIN; HEPARIN; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; METALLOPROTEINASE; NITINOL; PADGEM PROTEIN; PLACEBO; RIFAMPICIN; RITONAVIR; RIVAROXABAN; VASCULOTROPIN; VON WILLEBRAND FACTOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ATRIA RISK SCORE; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CARDIOVERSION; CHA2DS2 VASC RISK SCORE; CHADS2 RISK SCORE; DEEP VEIN THROMBOSIS; DEVICE THERAPY; DEVICES; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENDOCARDIUM; ENDOTHELIAL DYSFUNCTION; HAS BLED RISK SCORE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART CATHETERIZATION; HEART LEFT ATRIUM APPENDAGE PERCUTANEOUS CLOSURE; HEMORR2HAGES RISK SCORE; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; META ANALYSIS (TOPIC); MODEL; MORBIDITY; MORTALITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PAROXYSMAL ATRIAL FIBRILLATION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SECONDARY PREVENTION; SIDE EFFECT; SINUS RHYTHM; STROKE; THROMBOCYTE ACTIVATION; THROMBOEMBOLIC STROKE; THROMBOGENESIS;

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; CARDIAC SURGICAL PROCEDURES; ELECTRIC COUNTERSHOCK; HEART CATHETERIZATION; HEMORRHAGE; HUMANS; PATIENT SELECTION; PREVENTIVE HEALTH SERVICES; RISK ASSESSMENT; RISK FACTORS; SEPTAL OCCLUDER DEVICE; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84856102900     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32834f2336     Document Type: Review

References (90)

1. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009; 104:1534-1539.
2. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 2000; 4:369-382.
3. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110:1042-1046. (Pubitemid 39319000)
4. Stewart S, Hart CL, Hole DJ, et al. Population, prevalence, incidence and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86:516-521. (Pubitemid 32999861)
5. Kennel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82:2N-9N.
6. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98:476-484.
7. Bruggenjurgen B, Rossnagel K, Roll S, et al. The impact of atrial fibrillation on the cost of stroke: the Berlin acute stroke study. Value Health 2007; 10:137-143. (Pubitemid 46481140)
8. An economic model of stroke in atrial fibrillation: The cost of suboptimal oral anticoagulation Am. J. Manag. Care. 10 2004 S451-S458.
9. Virchow, R. Gesammelte abhandlungen zur wissenschaftlichen medizin. Frankfurt: Medinger Sohn & Co; 1856. pp. 219.
10. Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J 1995; 73:527-533.
11. Conway DS, Pearce LA, Chin BS, et al. Plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002; 106:1962-1967. (Pubitemid 35176302)
12. Goldsmith I, Kumar P, Carter P, et al. Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study. Am Heart J 2000; 140:777-784.
13. Freestone B, Lip GY, Chong AY, et al. Circulating endothelial cells in atrial fibrillation with and without acute cardiovascular disease. Thromb Haemost 2005; 94:702.
14. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996; 61:755-759. (Pubitemid 26060923)
15. Pollick C, Taylor D. Assessment of left atrial appendage function by transesophageal echocardiography. Implications for the development of thrombus. Circulation 1991; 84:223-231.
16. Manning WJ, Silverman DI, Katz SE, et al. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol 1994; 23:1535-1540. (Pubitemid 24182115)
17. Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol 1998; 82:1545-1547. (Pubitemid 29006485)
18. Di Tullio MR, Sacco RL, Sciacca RR, Homma S. Left atrial size and the risk of ischemic stroke in an ethnically mixed population. Stroke 1999; 30:2019-2024. (Pubitemid 29473243)
19. Lip GY. Intracardiac thrombus formation in cardiac impairment: the role of anticoagulant therapy. Postgrad Med J 1996; 72:731-738. (Pubitemid 27037832)
20. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features ofpatients at risk. Ann Intern Med 1992; 116:6-12.
21. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997; 336:251-257. (Pubitemid 27044626)
22. Lip GY. Hypercoagulability and haemodynamic abnormalities in atrial fibrillation. Heart 1997; 77:395-396. (Pubitemid 27278413)
23. Feinberg WM, Macy E, Cornell ES, et al. Plasmin-a2-antiplasmin complex in patients with atrial fibrillation. Thromb Haemost 1999; 82:100-103. (Pubitemid 29368780)
24. Lip GY, Lip PL, Zarifi s J, et al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996; 94:425-431. (Pubitemid 26266127)
25. Minamino T, Kitakaze M, Sanada S, et al. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. Circulation 1998; 98:1721-1727. (Pubitemid 28492491)
26. Marín F, Roldán V, Climent V, et al. Thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? Stroke 2003; 34:1181-1186. (Pubitemid 36547510)
27. Choudhury A, Chung I, Blann AD, Lip GY. Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of 'healthy control subjects and 'disease control subjects in sinus rhythm. J Am Coll Cardiol 2007; 49:1957-1964. (Pubitemid 46695928)
28. Igarashi Y, Yamaura M, Ito M, et al. Elevated serum lipoprotein(a) is a risk factor for left atrial thrombus in patients with chronic atrial fibrillation: a transesophageal echocardiographic study. Am Heart J 1998; 136:965-971. (Pubitemid 29080853)
29. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008; 39:1901-1910.
30. Gage BF, Waterman AD, Shannon W. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285:2864-2870.
31. Atrial Fibrillation Investigators: Atrial Fibrillation, Aspirin, Anticoagulation Study; Boston Area Anticoagulation Trial for Atrial Fibrillation Study; Canadian Atrial Fibrillation Anticoagulation Study; Stroke Prevention in Atrial Fibrillation Study; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Study. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449-1457.
32. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003; 290:1049-1056. (Pubitemid 37430445)
33. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl):546S- 592S.
34. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257-e354.
35. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285:2864-2870. (Pubitemid 32537350)
36. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004; 110:2287-2292. (Pubitemid 39407328)
37. Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: The EuroHeart Survey on Atrial Fibrillation. Chest 2010; 137:263-272.
38. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GYH. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 123: 638-645.e4.
39. Palareti G, Cosmi B. Bleeding with anticoagulation therapy-who is at risk, and how best to identify such patients. Thromb Haemost 2009; 102:268-278.
40. Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004; 35:2362-2367. (Pubitemid 39311264)
41. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151:713-719. (Pubitemid 43290267)
42. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105:91-99. (Pubitemid 28405230)
43. Kuijer PM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159:457-460. (Pubitemid 29108910)
44. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest 2010 [Epub ahead of print].
45. Fang M, Go AS, Chang Y, et al. A new risk scheme to predict warfarinassociated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol 2011; 58:395-401.
46. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1:175-179. (Pubitemid 19038801)
47. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84:527-539.
48. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323:1505-1511.
49. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18:349-355.
50. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327:1406-1412.
51. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342:1255-1262.
52. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42:227-276.
53. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349:1019-1026. (Pubitemid 37087616)
54. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333:5-10.
55. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes 2009; 2:297-304.
56. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996; 348:633-638.
57. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1:175-179. (Pubitemid 19038801)
58. Koefoed BG, Peterson P. Very low-intensity antithrombotic therapy in atrial fibrillation. J Thromb Thromb 1999; 7:67-71. (Pubitemid 29090124)
59. Connolly SJ, Ezekowitz MD, Yusuf S, et al., RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
60. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363:1875-1876.
61. The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators. Rivaroxaban: once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159:340-347.
62. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364:806-817.
63. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992.
64. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343:687-691.
65. Van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288:2441-2448. (Pubitemid 35340540)
66. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867. (Pubitemid 351650486)
67. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84:527-539.
68. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867. (Pubitemid 351650486)
69. Cooper NJ, Sutton AJ, Lu G, Khunti K. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med 2006; 166:1269-1275. (Pubitemid 43967578)
70. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367:1903-1912.
71. Connolly SJ, Pogue J, Hart RG, et al., ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360:2066-2078.
72. Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with nonrheumatic atrial fibrillation: results from the international multicenter feasibility trials. J Am Coll Cardiol 2005; 46:9-14. (Pubitemid 40905122)
73. Holmes DR, Reddy VY, Turi ZG, et al., PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized noninferiority trial. Lancet 2009; 374:534-542.
74. Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011; 123:417-424.
75. Bass JL. Transcatheter occlusion of the left atrial appendage: experimental testing of a new Amplatzer device. Catheter Cardiovasc Interv 2010; 76:181-185.
76. García-Fernández MA, Pé rez-David E, Quiles J, et al. Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study. J Am Coll Cardiol 2003; 42:1253-1258. (Pubitemid 37188352)
77. Kanderian AS, Gillinov AM, Pettersson GB, et al. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. J Am Coll Cardiol 2008; 52:924-929.
78. Bonow RO, Carabello BA, Chatterjee K, et al., 2006 Writing Committee Members, American College of Cardiology/American Heart Association Task Force. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008; 118:e523.
79. Biblo LA, Yuan Z, Quan KJ, et al. Risk of stroke in patients with atrial flutter. Am J Cardiol 2001; 87:346-349. (Pubitemid 32144882)
80. Ghali WA, Wasil BI, Brant R, et al. Atrial flutter and the risk of thromboembolism: a systematic review and meta-analysis. Am J Med 2005; 118:101-107. (Pubitemid 40202852)
81. Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000; 35:183-187. (Pubitemid 30061278)
82. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825-1833. (Pubitemid 35417773)
83. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent AF. N Engl J Med 2002; 347:1834-1840. (Pubitemid 35417774)
84. Kinch JW, Davidoff R. Prevention of embolic events after cardioversion of atrial fibrillation. Current and evolving strategies. Arch Intern Med 1995; 155:1353-1360.
85. Weigner MJ, Thomas LR, Patel U, et al. Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. Am J Med 2001; 110:694-702. (Pubitemid 32524318)
86. Klein AL, Grimm RA, Jasper SE, et al. Efficacy of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial. Am Heart J 2006; 151:380-389. (Pubitemid 43148982)
87. Stellbrink C, Nixdorff U, Hofmann T, et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004; 109:997-1003 (Pubitemid 38292177)
88. Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial brillation or utter: a retrospective analysis. Am J Cardiol 1998; 82:1545-1547. (Pubitemid 29006485)
89. Saxena R, Lewis S, Berge E, et al. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001; 32:2333-2337. (Pubitemid 32954805)
90. Hart RG, Palacio S, Pearce LA. Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. Stroke 2002; 33:2722-2727. (Pubitemid 35266448)